Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines the diagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger...

Early report Major update Updated Mar 6, 2026, 9:01 PM UTC

Track this event Edit in app More event pages

What changed

Early report surfaced from GlobeNewswire Public Companies 4h ago.

First seen Mar 6, 2026, 9:01 PM UTC Latest source Mar 6, 2026, 9:01 PM UTC

Update 1 4h ago

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

GlobeNewswire Public Companies •published Mar 6, 2026, 9:01 PM UTC •fetched Mar 6, 2026, 9:11 PM UTC

Event stats

Reports 1

Sources 1

Confidence low

Score 41

Entity focus

LantheusAnnouncesApprovalTruInjection

Source spread

GlobeNewswire Public Companies

Turn this into an alert

Draft the watch from the event wording, then let PushMe handle follow-up changes.

Notify me about major new developments on Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection, especially involving Lantheus, Announces, Approval.

Create alert from this event